Shanghai Junshi Biosciences (01877.HK) Announces October 2025 Monthly Return On Securities Movements

Bulletin Express
Nov 03

Shanghai Junshi Biosciences Co., Ltd. (01877.HK) released its monthly return for the period ended 31 October 2025, disclosing that its total registered share capital remains at RMB 1,026,689,871, comprising 260,295,700 H shares and 766,394,171 A shares. No increase or decrease was reported for both classes of shares during this month.

The issued H shares remained at 260,295,700. The issued A shares remained at 766,394,171, comprising 765,578,300 issued shares and 815,871 treasury shares. No changes were recorded in the treasury shares.

Regarding share option schemes, the H Share Option Incentive Scheme, approved on 29 September 2025, shows 13,210,000 outstanding share options, with no new shares issued during the month. The total number of shares that may be issued or transferred out of treasury upon exercise stands at 64,227,400. The A Share Option Incentive Scheme, also approved on 29 September 2025, reports 25,150,000 outstanding share options, with no new shares issued during the month. The total number of shares that may be issued or transferred out of treasury under this scheme is 815,871.

No other warrants, convertibles, or share issuance arrangements were in place, and no changes in Hong Kong Depositary Receipts were reported. The submission confirms that all regulatory requirements have been complied with and that no revisions to the company’s capital structure took place in October 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10